List view / Grid view
This series investigates cannabinoids and pharmaceutical interest with industry experts explaining the position of the ingredient. In this third piece, we discuss the future of the cannabinoid industry and how it will grow within the realm of pharmaceuticals.
The FDA has announced that it has granted approval to the first nine generic drug applications for Pfizer’s Lyrica treatment.
13 May 2015 | By Victoria White
The treatment market value for fibromyalgia across the seven major markets of the US, France, Germany, Italy, Spain, the UK, and Japan, will expand from $1.8 billion in 2013 at a tepid Compound Annual Growth Rate (CAGR) of 0.72% to reach $1.9 billion by 2023, according to research and consulting…
19 December 2014 | By Pfizer
Pfizer Inc. (NYSE:PFE) announced today top-line results from a double-blind Phase 3 study evaluating pregabalin controlled-release (CR) formulation in adult patients with postherpetic neuralgia (pain after shingles or PHN).
The study met its primary endpoint, showing a statistically significant greater reduction in fibromyalgia pain...
19 November 2012 | By Pfizer
Top-line results of a Phase 3 study...
16 November 2012 | By Pfizer
Pfizer Inc., announced top-line results of a double-blind, placebo-controlled, Phase 3 study...
19 July 2012 | By Pfizer
“The Court’s decision recognizes the infringement & validity of our LYRICA® patents..."
6 July 2012 | By Eli Lilly and Company
Eli Lilly and Company has met the United States FDA requirements for pediatric exclusivity for Cymbalta®...
18 May 2012 | By Pfizer
Results of studies on Lyrica® announced...
4 May 2012 | By Pfizer
Pfizer has stopped a Phase 3 clinical trial of Lyrica in patients with neuropathic pain...
4 May 2012 | By Pfizer
Pfizer announced that a Phase 3 randomized withdrawal design study for Lyrica in patients...
5 July 2011 | By Pfizer
Pfizer Japan announced the top-line results for Lyrica (pregabalin) Study A0081208...
